Jazz Pharmaceuticals PLC $JAZZ Shares Bought by UBS Group AG

Key Points

• UBS Group AG raised its stake in Jazz Pharmaceuticals by 2.9% in Q4 to 472,952 shares (about 0.78% ownership), a position valued at roughly $80.4 million; institutional investors hold about 89.14% of the stock.
• Insiders have been net sellers: EVP Neena M. Patil sold 55,600 shares for $10.65 million and insiders sold 74,015 shares totaling approximately $14.18 million in the last quarter, leaving insiders with about 4.30% ownership.
• Analysts are broadly bullish with a consensus rating of “Moderate Buy” and a $216.87 target after several firms raised price targets, and the company recently beat estimates with EPS of $6.64 and revenue of $1.20 billion.

UBS Group AG raised its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 2.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 472,952 shares of the specialty pharmaceutical company's stock after purchasing an additional 13,485 shares during the period. UBS Group AG owned 0.78% of Jazz Pharmaceuticals worth $80,402,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Farther Finance Advisors LLC raised its stake in Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company's stock valued at $35,000 after buying an additional 234 shares in the last quarter. Hilltop National Bank acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $36,000. Danske Bank A S acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $40,000. Quent Capital LLC bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at approximately $44,000. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock valued at $47,000 after acquiring an additional 137 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 55,600 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the sale, the executive vice president owned 56,862 shares of the company's stock, valued at approximately $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total value of $1,143,000.00. Following the transaction, the director owned 384,682 shares of the company's stock, valued at approximately $73,281,921. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 74,015 shares of company stock worth $14,180,486 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

JAZZ has been the topic of a number of research reports. Wells Fargo & Company increased their target price on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Leerink Partners lifted their price target on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an "outperform" rating in a report on Wednesday, April 22nd. Bank of America boosted their price objective on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. TD Cowen reiterated a "buy" rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. Finally, Truist Financial raised shares of Jazz Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $216.87.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $202.72 on Monday. Jazz Pharmaceuticals PLC has a 1 year low of $97.50 and a 1 year high of $207.48. The company has a market cap of $12.72 billion, a price-to-earnings ratio of -33.96, a price-to-earnings-growth ratio of 0.35 and a beta of 0.27. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86. The firm has a fifty day moving average of $189.65 and a 200-day moving average of $171.11.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts' consensus estimates of $6.49 by $0.15. The business had revenue of $1.20 billion for the quarter, compared to analysts' expectations of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The company's revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter last year, the company earned $6.51 EPS. As a group, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 20.51 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.